Not Too Late to Own ANI Pharmaceuticals (ANIP), Guggenheim Says
Get Alerts ANIP Hot Sheet
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Guggenheim analyst Louise Chen reiterated a Buy rating and $79 price target on ANI Pharmaceuticals (NASDAQ: ANIP) following meetings with management.
Chen commented, "We remain positive on ANIP shares after hosting meetings with CEO, Art Przybyl, and CFO, Charlotte Arnold on 3/4/15. Although ANIP has outperformed (up +18% vs. S&P500 +2%) we would still be buyers because we continue to believe a large number of new approvals over the next 12 months should drive earnings growth to levels not reflected in consensus. Moreover, we expect more product acquisitions following ANIP’s recent $144MM convertible debt offering. Finally, we think ANIP's valuation is inexpensive. Companies with lower EBITDA forecasts for '15 have higher market caps than ANIP, like SGNT (NEUTRAL, $27.40) and IG (NC, $9.43)."
For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.
Shares of ANI Pharmaceuticals closed at $66.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs on Meta Platforms Inc. (META): 'We expect investors to have an initial negative reaction'
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- First Mid Bancshares, Inc. (FMBH) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Standard & Poor's, Earnings, Louise ChenSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!